Anti-CD20 in Systemic Lupus Erythematosus

• ClinicalTrials.gov Identifier: NCT00036491
• Recruitment Status: Completed
• First Posted: May 13, 2002
• Last Update Posted: November 6, 2017
• Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Collaborator: Autoimmunity Centers of Excellence
• Information provided by (Responsible Party): National Institute of Allergy and Infectious Diseases (NIAID)

Study Description

Brief Summary:

The purpose of this study is to determine the safety and effectiveness of rituximab (anti-CD20) in treating systemic lupus erythematosus (SLE).

White blood cells in the body called B cells give off substances that are active in promoting SLE disease. Researchers have found that anti-CD20 can block production of these substances in another disease. This study explores whether anti-CD20 will also be safe in people with SLE and whether it may be effective in treating SLE.

Condition or disease	Intervention/treatment	Phase
Lupus Erythematosus, Systemic	Drug: Rituximab	Phase 1; Phase 2

Detailed Description:

B cells clearly play an essential role in the pathogenesis of SLE since they produce autoantibodies. Clinical observations support the contention that intervening in the production of autoantibodies by the B lymphocyte will be effective therapy. Current approved therapy for B-cell non-Hodgkin's lymphoma includes anti-CD20. The results of anti-CD20 administration in SLE are anticipated to be similar to those in lymphoma patients. The current proposal explores the mechanisms and applicability of B-cell depletion as a potential treatment for SLE.

Participants receive 4 weekly infusions of study medication. Each participant is enrolled in the study for a total of 1 year with protocol visits weekly for the first 3 months, then every other week for the next 2 months, every month for the next 4 months, and every other month for the remaining 5 months of the study (Weeks 0, 1, 2, 3, 4, 5, 6, 7, 9, 11, 13, 15, 19, 23, 27, 31, 39, 47, and 55). Responses to exogenous antigens are measured; assessments for clinical response with SLE-disease activity score (SLEDEI) and systemic lupus activity measure (SLAM) score are performed. Participants complete a health questionnaire and a health survey and laboratory parameters are evaluated.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 24 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-Label Safety and Efficacy Study of an Anti-CD20 Antibody (Rituximab, Rituxan®) for Anti-B Cell Therapy in the Treatment of Systemic Lupus Erythematosus
• Study Start Date: January 2001
• Actual Primary Completion Date: January 2006
• Actual Study Completion Date: January 2006

Arms and Interventions

Arm	Intervention/treatment
Experimental: rituximab; 375 mg/m^2 administered intravenously	Drug: Rituximab; Subjects received four weekly infusions of rituximab at a dose of 375 mg/m^2; Other Name: Rituxan®

Outcome Measures

Primary Outcome Measures :

1. Serum Autoantibodies [ Time Frame: Baseline, Week 4, Week 12, Week 24, Week 36 and Week 56 ]
2. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [ Time Frame: Baseline, Week 4, Week 7, Week 11, Week 15, Week 19, Week 27, Week 39 and Week 55 ]

Secondary Outcome Measures :

1. C3 and C4 complement levels
2. Systemic Lupus Activity Measure (SLAM) [ Time Frame: Baseline, Week 4, Week 7, Week 11, Week 15, Week 19, Week 27, Week 39 and Week 55 ]
3. Erythrocyte Sedimentation Rate (ESR)
4. Prednisone Dose [ Time Frame: Baseline, Week 4, Week 12, Week 24, Week 36 and Week 56 ]
5. Renal Function
   Measured by creatinine clearance and total protein.
6. Modified Health Assessment Questionnaire (HAQ)
7. Short Form-36 Health Survey (SF-36)
8. Physician Global Assessment (VAS)
9. Patient Global Assessment (VAS)
10. Systemic Lupus Erythematosus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index for SLE
11. Adverse Events

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria

People may be eligible for this study if they:

• Are 18 to 70 years of age
• Agree to use a reliable method of birth control during treatment and for 6 months after treatment ends
• Have SLE (by the American College of Rheumatology criteria)
• Have had SLE for at least 6 months prior to screening
• Have active SLE disease at the screening visit
• Have organ disease (lung, stomach, intestinal, blood, kidney, and/or heart)
• Have failed standard therapy, including at least 1 immunosuppressive agent, or have experienced side effects from an immunosuppressive agent that required discontinuation of treatment
• Meet blood, liver, and kidney laboratory values set by the protocol
• Have not taken an immunosuppressive agent for 2 weeks prior to the first treatment
• Have been on a stable dose of oral corticosteroids, if taking them, for 4 weeks before the first week's visit. Oral corticosteroids may be altered as medically necessary after enrollment.
• Have at least 1 elevated autoantibody level at screening visit.

Exclusion Criteria

People will not be eligible for this study if they:

• Are pregnant or breast-feeding
• Have heart, lung, nervous system, kidney, liver, stomach, intestinal, or other diseases that may place the patient at risk if participating in the trial
• Have cranial neuropathy (a condition affecting the head region)
• Are on blood-thinning agents to prevent blood clotting
• Have a serious skin disease
• Have a certain class of heart disease
• Have had cancer, unless surgically cured basal cell carcinoma or cervical dysplasia
• Have a long term serious infectious disease such as tuberculosis or a fungal infection that is now active, or active within 2 years of the baseline visit
• Have had HIV infection or another immunosuppressive state (chemotherapy or radiation therapy)
• Have received any experimental drug within 30 days of baseline visit
• Have received any monoclonal antibody or similar medication within 3 months of the baseline visit
• Received any intravenous, joint, or muscle injection of corticosteroids within 4 weeks of the baseline visit
• Abuse alcohol or drugs
• Are unwilling or unable to follow the protocol
• Have poor veins for receiving injections.

Contacts and Locations

Locations

United States, Colorado

University of Colorado

Denver, Colorado, United States, 80045

United States, New York

University of Rochester

Rochester, New York, United States, 14623

United States, Pennsylvania

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Autoimmunity Centers of Excellence

Investigators

• Study Chair: Robert A. Eisenberg, MD; University of Pennsylvania

More Information

Additional Information:

National Institute of Allergy and Infectious Diseases (NIAID) 

Autoimmunity Centers of Excellence (ACE) 

Study Data/Documents: Individual Participant Data Set 

Identifier: SDY625
Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.

Study Protocol 

Identifier: SDY625
ImmPort study identifier is SDY625.

Study summary, -design, -adverse event(s), -summary of participant assessments, -interventions, -medications, -demographics, -lab tests, -study files, et al. 

Identifier: SDY625
ImmPort study identifier is SDY625.

Publications of Results:

Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008 Dec;67(12):1724-31. doi: 10.1136/ard.2007.083162. Epub 2008 Feb 4.

Other Publications:

Eisenberg R. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):345-50. doi: 10.2174/187153006779025757.

Sutter JA, Kwan-Morley J, Dunham J, Du YZ, Kamoun M, Albert D, Eisenberg RA, Luning Prak ET. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol. 2008 Mar;126(3):282-90. doi: 10.1016/j.clim.2007.11.012. Epub 2008 Jan 15.

• Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
• ClinicalTrials.gov Identifier: NCT00036491
• Other Study ID Numbers: DAIT AC002; SACCC #ASL02 ( Other Identifier: Statistical and Clinical Coordinating Center ); UPenn #U1131s ( Other Identifier: University of Pennsylvania ); ACE Study #AC002 ( Other Identifier: Autoimmunity Centers of Excellence )
• First Posted: May 13, 2002
• Last Update Posted: November 6, 2017
• Last Verified: November 2017

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

Systemic Lupus Erythematosus; SLE; B-Lymphocytes; anti-CD20; rituximab

Additional relevant MeSH terms:

Lupus Erythematosus, Systemic; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Rituximab; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents